1. FUSTER, V., BADIMON, L., BADIMON, J., ADAMS, P.C., TURITTO, V. and CHESEBRO, J.M., Drugs interfering with platelet functions: mechanisms and clinical relevance. In: Thrombosis and Hemostasis. M. Verstraete, J. Vermylen, R. Lijnen, J. Arnout (eds.), pp.349–418, Raven Press, New York (1987).
2. Platelet-vessel wall interactions: implications of 5-hydroxytryptamine. A review;DE CLERCK;Agents and Actions,1984
3. DE CLERCK, F. and DE CHAFFOY DE COURCELLES, D., Amplification mechanisms in platelet activation. In: Blood cells and arteries in hypertension and atherosclerosis. P. Meyer, P. Marche (eds.), pp.105–140, Raven Press, New York, (1989).
4. VAN NUETEN, J.M., JANSSEN, P.A.J. and SYMOENS, J., Ketanserin. In: New cardiovascular drugs. A. Scriabine (ed.), pp.1–56, Raven Press, New York, (1987).
5. Biochemical abnormalities of platelets in renal failure;EKNOYAN;Am J Nephrol,1981